-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the rise of the face value economy, the medical beauty market has emerged as a blue oce.
According to Frost & Sullivan data, the compound growth rate of the medical beauty industry in the past five years has been 19% (affected by the epidemic in 2020, the growth rate will slow down), and it will maintain a compound growth rate of 15% in the next 10 yea.
In 2020, the scale of China's regular medical beauty market is about 159 billion yuan, and the overall scale is expected to exceed 300 billion yuan in 202 Facing the attraction of the 100 billion market, medical beauty has become a cross-border treasure, including many pharmaceutical companies that have set foot in this field to seek breakthroughs under the heavy pressure of industry polici.
For example, at the end of 2021, Yunnan Baiyao plans to increase its capital by 500 million yuan to its subsidiary Yunzhen Company, and actively promote the ecological layout of the medical beauty industry cha.
It is reported that Yunzhen Company will be the setting unit of Yunnan Baiyao Skin Comprehensive Solution Medical Center, with the opening of the outpatient department as the entry point, actively promote the ecological layout of the medical beauty industry chain, explore the upstream and downstream business growth models, and quickly open up the business track , the layout of the whole ecological chain cycle of the big health indust.
On December 30, 2021, Sihuan Pharmaceutical announced that Yaozhong International, a subsidiary of the company, signed an acquisition agreement with the original shareholder "Seller" of Genesis in the United States, and Yaozhong International would acquire all the equity of Genes.
It is reported that Genesis is a manufacturer of high-quality aesthetic and biomedical produc.
As early as 2014, Sihuan Pharmaceutical signed an agency agreement for botulinum toxin and hyaluronic acid products with South Korea’s Hugel Company, and entered the field of medical beau.
The acquisition will further expand the Group's medical aesthetic product pipeline, consolidate the Group's comprehensive layout in the non-surgical and surgical medical aesthetic fields, and further accelerate the development of the Group's medical aesthetic business from a product agency to an integrated platform enterpri.
In addition to Yunnan Baiyao and Sihuan Pharmaceutical, according to incomplete statistics, there are currently more than 30 listed pharmaceutical companies in the field of medical beauty, including Huadong Medicine, Fosun Pharmaceutical, Teyi Pharmaceutical, Changshan Pharmaceutical, Kangzhe Pharmaceutical, Jiangsu Wu Zhong Enterprise
The industry pointed out that medical aesthetics has strict management and control requirements, and pharmaceutical companies themselves are deeply involved in this fie.
Therefore, cross-border medical aesthetics of pharmaceutical companies has strong mobility in terms of quality management, talent echelon, technology accumulation, and sales channe.
So, have these pharmaceutical companies in the cross-border 100 billion medical beauty market become "beautiful"? Judging from the 2021 annual reports and 2022 first quarter reports disclosed by major companies recently, some companies have indeed entered the harvest peri.
For example, the 2021 financial report released by Huadong Medicine recently shows that in 2021, Huadong Medicine achieved operating income of 3563 billion yuan, a year-on-year increase of 61%; in the first quarter of 2022, the company's performance continued to grow, achieving operating income of 933 billion yuan, a year-on-year increase of 4%; Net profit after deduction of non-deductible items was 699 million yuan, a year-on-year increase of 3
From the perspective of business sectors, the performance of Huadong Medicine's medical beauty business has grown significant.
Among them, in the international market, the financial report shows that in 2021, Sinclair, a subsidiary of Huadong Medicine’s international medical beauty business, will achieve a consolidated operating income of about 665 million yuan, a year-on-year increase of 105
Among them, Sinclair's own revenue increased by 724%, the company's EBITBA achieved a profit of 66 million pounds for the whole year, a record high, and the global market for the core product "Girl Needle" (polycaprolactone microsphere facial filler for injection) achieved 99% grow.
In the domestic market, Xin Keli Aesthetics, its domestic medical beauty business subsidiary, achieved an operating income of 185 million yuan, and its operating income in the first quarter of this year reached 157 million yuan, which is also very outstandi.
It is reported that in the medical beauty sector, Huadong Medicine has 35 medical beauty products, of which 21 are listed at home and abro.
The product portfolio covers facial filling, thread embedding, skin management, body shaping,e.
At present, Huadong Medicine's cross-border medical beauty business has been recognized by domestic and foreign markets, and has developed into one of the company's core business segmen.
The growth of Sihuan Pharmaceutical's medical beauty business is also very gratifyi.
According to the company's 2021 financial report, Sihuan Pharmaceutical's medical beauty business revenue in 2021 is about 400 million yuan, a year-on-year increase of 1300%, accounting for 12% of the total revenue of 291 billion yuan for the year
It is reported that the sharp increase in its medical beauty business is mainly due to the fact that the botulinum toxin Letibao, which focuses on cost-effective and affordable luxury, has been listed for sale, which has led to a rapid increase in reven.
It is reported that botulinum toxin is a strictly regulated variety with a long approval ti.
At present, there are only 4 models on the domestic market, while Sihuan Pharmaceutical has the advantage of card positi.
Another example is Fosun Phar.
In 2013, the company established its subsidiary, Furui Medical Technology, to enter the medical beauty track, and completed the acquisition of Alma Laser, an Israeli medical beauty equipment manufactur.
Today, Furui Medical Technology has become a large-scale supplier of energy source medical beauty equipment in the Chinese mark.
According to the 2021 annual report, Sisram will achieve an operating income of US$294 million and a net profit of US$352 million in 2021, a substantial increase year-on-ye.
According to the industry, whether cross-border medical and aesthetic pharmaceutical companies can achieve certain breakthroughs in the short and medium term depends on the vision of pharmaceutical companies and their ability to link resourc.
From the perspective of the means of Huadong Medicine and Sihuan Pharmaceutical's medical aesthetics layout, the two mainly enter the medical aesthetics track through agents and buy-buy-buy, which is also the way most pharmaceutical companies expand their medical aesthetics business, while Fosun Pharma is " Self-developed" enterpri.
"In the long run, pharmaceutical companies may also need to maintain strong innovation in cross-border medical aesthetics in order to make long-term profi.
" Disclaimer: In any case, the information or opinions expressed in this article do not constitute any investment advi.
According to Frost & Sullivan data, the compound growth rate of the medical beauty industry in the past five years has been 19% (affected by the epidemic in 2020, the growth rate will slow down), and it will maintain a compound growth rate of 15% in the next 10 yea.
In 2020, the scale of China's regular medical beauty market is about 159 billion yuan, and the overall scale is expected to exceed 300 billion yuan in 202 Facing the attraction of the 100 billion market, medical beauty has become a cross-border treasure, including many pharmaceutical companies that have set foot in this field to seek breakthroughs under the heavy pressure of industry polici.
For example, at the end of 2021, Yunnan Baiyao plans to increase its capital by 500 million yuan to its subsidiary Yunzhen Company, and actively promote the ecological layout of the medical beauty industry cha.
It is reported that Yunzhen Company will be the setting unit of Yunnan Baiyao Skin Comprehensive Solution Medical Center, with the opening of the outpatient department as the entry point, actively promote the ecological layout of the medical beauty industry chain, explore the upstream and downstream business growth models, and quickly open up the business track , the layout of the whole ecological chain cycle of the big health indust.
On December 30, 2021, Sihuan Pharmaceutical announced that Yaozhong International, a subsidiary of the company, signed an acquisition agreement with the original shareholder "Seller" of Genesis in the United States, and Yaozhong International would acquire all the equity of Genes.
It is reported that Genesis is a manufacturer of high-quality aesthetic and biomedical produc.
As early as 2014, Sihuan Pharmaceutical signed an agency agreement for botulinum toxin and hyaluronic acid products with South Korea’s Hugel Company, and entered the field of medical beau.
The acquisition will further expand the Group's medical aesthetic product pipeline, consolidate the Group's comprehensive layout in the non-surgical and surgical medical aesthetic fields, and further accelerate the development of the Group's medical aesthetic business from a product agency to an integrated platform enterpri.
In addition to Yunnan Baiyao and Sihuan Pharmaceutical, according to incomplete statistics, there are currently more than 30 listed pharmaceutical companies in the field of medical beauty, including Huadong Medicine, Fosun Pharmaceutical, Teyi Pharmaceutical, Changshan Pharmaceutical, Kangzhe Pharmaceutical, Jiangsu Wu Zhong Enterprise
The industry pointed out that medical aesthetics has strict management and control requirements, and pharmaceutical companies themselves are deeply involved in this fie.
Therefore, cross-border medical aesthetics of pharmaceutical companies has strong mobility in terms of quality management, talent echelon, technology accumulation, and sales channe.
So, have these pharmaceutical companies in the cross-border 100 billion medical beauty market become "beautiful"? Judging from the 2021 annual reports and 2022 first quarter reports disclosed by major companies recently, some companies have indeed entered the harvest peri.
For example, the 2021 financial report released by Huadong Medicine recently shows that in 2021, Huadong Medicine achieved operating income of 3563 billion yuan, a year-on-year increase of 61%; in the first quarter of 2022, the company's performance continued to grow, achieving operating income of 933 billion yuan, a year-on-year increase of 4%; Net profit after deduction of non-deductible items was 699 million yuan, a year-on-year increase of 3
From the perspective of business sectors, the performance of Huadong Medicine's medical beauty business has grown significant.
Among them, in the international market, the financial report shows that in 2021, Sinclair, a subsidiary of Huadong Medicine’s international medical beauty business, will achieve a consolidated operating income of about 665 million yuan, a year-on-year increase of 105
Among them, Sinclair's own revenue increased by 724%, the company's EBITBA achieved a profit of 66 million pounds for the whole year, a record high, and the global market for the core product "Girl Needle" (polycaprolactone microsphere facial filler for injection) achieved 99% grow.
In the domestic market, Xin Keli Aesthetics, its domestic medical beauty business subsidiary, achieved an operating income of 185 million yuan, and its operating income in the first quarter of this year reached 157 million yuan, which is also very outstandi.
It is reported that in the medical beauty sector, Huadong Medicine has 35 medical beauty products, of which 21 are listed at home and abro.
The product portfolio covers facial filling, thread embedding, skin management, body shaping,e.
At present, Huadong Medicine's cross-border medical beauty business has been recognized by domestic and foreign markets, and has developed into one of the company's core business segmen.
The growth of Sihuan Pharmaceutical's medical beauty business is also very gratifyi.
According to the company's 2021 financial report, Sihuan Pharmaceutical's medical beauty business revenue in 2021 is about 400 million yuan, a year-on-year increase of 1300%, accounting for 12% of the total revenue of 291 billion yuan for the year
It is reported that the sharp increase in its medical beauty business is mainly due to the fact that the botulinum toxin Letibao, which focuses on cost-effective and affordable luxury, has been listed for sale, which has led to a rapid increase in reven.
It is reported that botulinum toxin is a strictly regulated variety with a long approval ti.
At present, there are only 4 models on the domestic market, while Sihuan Pharmaceutical has the advantage of card positi.
Another example is Fosun Phar.
In 2013, the company established its subsidiary, Furui Medical Technology, to enter the medical beauty track, and completed the acquisition of Alma Laser, an Israeli medical beauty equipment manufactur.
Today, Furui Medical Technology has become a large-scale supplier of energy source medical beauty equipment in the Chinese mark.
According to the 2021 annual report, Sisram will achieve an operating income of US$294 million and a net profit of US$352 million in 2021, a substantial increase year-on-ye.
According to the industry, whether cross-border medical and aesthetic pharmaceutical companies can achieve certain breakthroughs in the short and medium term depends on the vision of pharmaceutical companies and their ability to link resourc.
From the perspective of the means of Huadong Medicine and Sihuan Pharmaceutical's medical aesthetics layout, the two mainly enter the medical aesthetics track through agents and buy-buy-buy, which is also the way most pharmaceutical companies expand their medical aesthetics business, while Fosun Pharma is " Self-developed" enterpri.
"In the long run, pharmaceutical companies may also need to maintain strong innovation in cross-border medical aesthetics in order to make long-term profi.
" Disclaimer: In any case, the information or opinions expressed in this article do not constitute any investment advi.
